The emergence of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants of concern threatens the efficacy of currently approved vaccines and authorized …

Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …

SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding
domain (RBD) and N-terminal domain (NTD). Here we report the humoral immune response …

Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain …

Summary The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-
binding domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged
coronavirus that is responsible for the current pandemic of coronavirus disease 2019 …

Abstract SARS-CoV-2 501Y. V2 (B. 1.351), a novel lineage of coronavirus causing COVID-
19, contains substitutions in two immunodominant domains of the spike protein. Here, we …

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates …

Abstract The SARS-CoV-2 Omicron variant is more immune evasive and less virulent than
other major viral variants that have so far been recognized,,,,,,,,,,–. The Omicron spike (S) …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Beta variant of concern
(VOC) resists neutralization by major classes of antibodies from COVID-19 patients and …